Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

TW's Take: while feeling like this deal wasn't necessary in front of their July PDUFA date, the financing could be a great buying opportunity...

Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority...

Tailwinds Take: now the clock ticks to what should be (in our opinion) an approval on July 2nd.  RED BANK, N.J., Jan. 4, 2021 /PRNewswire/...

Climbing The Wall Of Worry…

That certainly was a crazy week. The news from our companies was positive, the news on the CoronaVirus was negative, volatility within our coverage...

JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection

Tailwinds' Take: increased detection will certainly help increase the market size for tepluzimab once approved. NEW YORK and RED BANK, N.J., Dec. 8, 2020 /PRNewswire/...

The Micro-Cap Rally Continues Full Force

November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...

Timing Is Everything…Or Is It?

The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...

Moving Week

What do Donald Trump and I have in common? We are both in the process of moving... This week we found out that Joe Biden...

Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for...

Tailwinds' Take: expected, but nice to see the company is on schedule with their submission. PRVB has a blockbuster drug here and will likely...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical...

Tailwinds' Take: an important step towards a BLA filing, which remains on track for sometime in Q4. We believe PRVB will trade higher into...

Shaking Things Up…

One of my investors recently told me that he diversifies his portfolio on his own. The money I manage for him is meant to...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

Tailwinds' Take: we are getting very close to the FDA BLA submission in Q4, which will be the major catalyst to get shares in...

Random Thoughts on a Number of Stocks…

There's certainly a lot going on in the world at large right now and none of it seems too good. Covid-19 refuses to go...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Provention Bio’s Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes...

Tailwinds' Take: excellent news for PRVB. Filing of IND in Q4 and approval early next year should be very big catalysts for this stock. OLDWICK,...

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of...

OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

Tailwinds' Take: all systems go for tepluzimab. We expect the stock to continue performing well as the company gets closer to the anticipated approval...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.